Gilead Acquires Repare's Polymerase Theta Program: Strategic Oncology Asset Reaches $30M Deal

2025-12-31 15:34:11

Repare Therapeutics Inc. (RPTX) has successfully finalized a transaction with Gilead Sciences (GILD) for the acquisition of RP-3467, an advanced polymerase theta ATPase inhibitor designed to target synthetic lethality mechanisms in cancer treatment. The deal encompasses a total value of $30 million, structured with a $25 million initial payment upon signing and a $5 million conditional milestone tied to technology transfer execution.

Drug Profile and Clinical Development

RP-3467 represents a potent small-molecule therapeutic targeting polymerase theta (Pol?), a validated mechanism for addressing BRCA-deficient tumors and related genomic instabilities. The compound is actively progressing through the POLAR Phase 1 clinical trial, currently assessing its efficacy as a monotherapy and in combination with olaparib across multiple cancer indications including advanced presentations of breast, ovarian, pancreatic, and prostate malignancies.

Strategic Implications for Repare

This transaction constitutes Repare’s third portfolio monetization event in 2025 and represents the most substantial to date. The $25 million upfront infusion strengthens Repare’s liquidity position ahead of its planned acquisition by Xeno Therapeutics. Updated valuations suggest RPTX shareholders will receive approximately $2.20 per share upon completion of the Xeno transaction.

CEO Steve Forte noted: “This agreement demonstrates how Gilead’s oncology capabilities align with RP-3467’s potential to become a best-in-class polymerase theta ATPase inhibitor in the market.”

Market Context and Stock Performance

The transaction underscores Gilead’s strategic expansion into oncology space and synthetic lethality-based approaches. RPTX stock has demonstrated notable momentum, trading at $2.62 in pre-market activity—a 20.73% increase that established a new 52-week high. Over the trailing twelve months, the stock has ranged between $0.89 and $2.30, reflecting the volatility characteristic of clinical-stage biotechnology companies navigating late-stage development milestones.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.